Edition:
United States

Reata Pharmaceuticals Inc (RETA.OQ)

RETA.OQ on NASDAQ Stock Exchange Global Market

26.73USD
16 Feb 2018
Change (% chg)

$-0.36 (-1.33%)
Prev Close
$27.09
Open
$27.19
Day's High
$27.38
Day's Low
$25.62
Volume
60,075
Avg. Vol
63,816
52-wk High
$40.56
52-wk Low
$19.85

Select another date:

Mon, Feb 12 2018

BRIEF-Reata Announces Improvements In Kidney Function With Bardoxolone Methyl Maintained For Two Years In Pah Patients From Lariat Trial

* REATA ANNOUNCES IMPROVEMENTS IN KIDNEY FUNCTION WITH BARDOXOLONE METHYL MAINTAINED FOR TWO YEARS IN PAH PATIENTS FROM LARIAT TRIAL Source text for Eikon: Further company coverage:

BRIEF-Reata Pharmaceuticals- Entered Third Supplement To Exclusive License & Supply Agreement With Kyowa Hakko

* REATA PHARMACEUTICALS-ON DEC 7 CO ENTERED THIRD SUPPLEMENT TO EXCLUSIVE LICENSE & SUPPLY AGREEMENT, BY & BETWEEN CO, KYOWA HAKKO KIRIN CO LTD (KHK)

BRIEF-Reata Pharmaceuticals files for offering of up to $50.0 million of shares of Class A common stock‍​

* Files for offering of up to $50.0 million of shares of Class A common stock‍​ - SEC filing Source text : (http://bit.ly/2AG2XNP) Further company coverage:

BRIEF-Reata Pharmaceuticals Q3 loss per share $0.50

* Reata Pharmaceuticals Inc announces third quarter 2017 financial and operating results

BRIEF-Reata Pharmaceuticals enters first amendment to loan and security agreement​

* Reata Pharmaceuticals says ‍on November 3, co entered into a first amendment to loan and security agreement​ - SEC filing

BRIEF-Reata provides update on Bardoxolone Methyl from American Society of Nephrology Kidney Week Meeting

* Reata provides update on bardoxolone methyl from the american society of nephrology kidney week meeting

BRIEF-Reata Pharmaceuticals says top-line data to be available in 2019 for omaveloxolone​

* Reata Pharmaceuticals Inc - ‍announces first patient enrolled in Part 2 of Moxie study of omaveloxolone for treatment of Friedreich's Ataxia​

BRIEF-Reata Pharma receives orphan drug designation for Omaveloxolone

* Reata Pharmaceuticals Inc receives orphan drug designation for Omaveloxolone for the treatment of malignant melanoma

Select another date: